Emyria Ltd: Emyria Shares Interim Success in PTSD Treatment Program
Emyria Ltd: June 2024 Quarterly Activities Report and Appendix 4C
Emyria Ltd: Emyria, UWA Secure $499K Grant for MDMA Analogue Program
Emyria Ltd: Empax Centre Selected As Key Site In Global PTSD Study
Emyria Ltd: Management Changes
Emyria Ltd: March 2024 Quarterly Activities Report and Appendix 4C
Emyria Ltd: Trading Halt
Emyria Ltd: Emyria Opens Empax Centre to Advance Mental Health Care
Emyria Ltd: Emyria Expands Specialist AP Team - First Female for MDMA-AT
Emyria Ltd: Emyria, Reach Wellness Enter MDMA-AT Research Agreement
Emyria Ltd: Response to ASX Aware Query
Emyria Ltd: Response to ASX Price Query
Emyria Ltd: December 2023 Quarterly Activities Report and Appendix 4C
Emyria Ltd: Emyria Receives $2.5M R&D Tax Incentive Refund
Emyria Ltd: Emyria Specialist Granted Authorised Prescriber Status
Emyria Ltd: Change of Director's Interest Notice - M. Winlo
Emyria Ltd: Initial Director's Interest Notice - G. Hutchinson
Emyria Ltd: Final Director's Interest Notice - S. Washer
Emyria Ltd: Eminent Healthcare Leader New Independent Non-Exec Chair
Emyria Ltd: Final Director's Interest Notice - A. Vickery
No Data